Clinical Follow-up Study of Rituximab in the Treatment of Nephrotic Syndrome in Children
Recruiting
Observational Study
Nephrotic Syndrome
Rituximab
Children
Efficacy
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
No Study Drug
Researchers observe your health over time — no experimental treatment is given.
At a Glance
- Age
- 1 – 18
- Sex
- Any
- Study type
- Observational
- Participants needed
- 50 (estimated)
- Sponsor
- The First Affiliated Hospital of Xiamen University · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
This was a retrospective study. Children who were diagnosed with refractory nephrotic syndrome and treated with rituximab (RTX) and followed up for ≥1 year in the Department of Pediatrics, the First Affiliated Hospital of Xiamen University from March 2020 to March 2026 were enrolled. Personal information, past medical history, clinical examination data and follow-up data before and after the use o…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Children clinically diagnosed with FRNS/SDNS/SRNS with complete clinical data;
* age \< 18 years old;
* For the first time using RTX treatment, and used in nephrotic syndrome ease;
* The follow-up for 1 year or more.
Exclusion Criteria:
* Congenital or infantile nephrotic sy…
Contacts